Revolutionizing Cardiac Rhythm Management
Abbott achieved a major milestone by completing the world’s first leadless left bundle branch area pacing (LBBAP) procedures using its investigational Aveir CSP leadless pacemaker. This marks a significant leap in addressing slow heart rhythms by mimicking the heart’s natural electrical conduction.
Key Highlights
- Pioneering Physicians: Procedures performed by Dr. Petr Neužil (Na Homolce Hospital, Prague) and Dr. Vivek Y. Reddy (Mount Sinai Hospital, New York).
- Groundbreaking Approach: First-ever implantation of a leadless pacemaker in the left bundle branch area.
- Study Objective: Part of the Leadless CSP feasibility study to evaluate safety and performance.
Innovative Technology
Abbott’s Aveir CSP system combines conduction system pacing (CSP) with leadless pacemaker technology, delivering critical benefits:
- Physiological Pacing: Activates the left bundle branch area to replicate the heart’s natural rhythm.
- Leadless Design: Eliminates the complications of traditional leads and pulse generators.
- Enhanced Safety: Reduces risks associated with lead- and pocket-related complications.
“Integrating proven leadless pacemaker technology with CSP has the potential to redefine cardiac care,” said Randel Woodgrift, SVP of Abbott’s cardiac rhythm management business.
FDA Breakthrough Designation
The Aveir CSP system’s FDA breakthrough designation underscores its potential to transform treatment for slow or irregular heart rhythms, offering patients safer and more effective care.
Shaping the Future of Cardiac Care
Abbott’s leadless CSP innovation paves the way for advancements in cardiac rhythm management, promising better outcomes and fewer complications for millions of patients.
Stay tuned with MEDWIRE.AI for more updates on groundbreaking cardiac technologies and innovations.
